Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 6.1M | 482.2% |
| Gross Profit | -30M | 61.4% |
| Cost of Revenue | 36M | 26.8% |
| Operating expense | 86M | 14% |
| Net Income | -86M | 36.3% |
| EBITDA | -56M | 46.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 365M | 17.9% |
| Total Liabilities | 1.11B | 2.9% |
| Shares Outstanding | 697M | 0.7% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -99M | 1.6% |
| Cash from investing | 65M | 226.3% |
| Cash from financing | 16M | 89.5% |
EPS
Financial Highlights for Immunitybio in Q3 '24
Immunitybio reported a revenue of 6.1M, which is a 482.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -30M, marking a 61.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 36M, a -26.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 86M, showing a -14% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -86M, showing a 36.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -56M, showing a 46.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Immunitybio with growth in revenue, gross profit, and net income.
